Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.438 USD
−62.26 M USD
163.91 M USD
141.35 M
About Xeris Biopharma Holdings, Inc.
Sector
Industry
CEO
John Patrick Shannon
Website
Headquarters
Chicago
Founded
2005
FIGI
BBG012YNKCH9
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
X
XERS5008737
Xeris Pharmaceuticals, Inc. 5.0% 15-JUL-2025Yield to maturity
0.93%
Maturity date
Jul 15, 2025
XERS5927663
Xeris Biopharma Holdings, Inc. 8.0% 15-JUL-2028Yield to maturity
−0.49%
Maturity date
Jul 15, 2028
Explore more bonds
Frequently Asked Questions
The current price of 0A8E is 3.506 USD — it has increased by 3.70% in the past 24 hours. Watch XERIS BIOPHARMA HLDGS INC COM USD0.0001 stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange XERIS BIOPHARMA HLDGS INC COM USD0.0001 stocks are traded under the ticker 0A8E.
0A8E stock has risen by 2.19% compared to the previous week, the month change is a 13.72% rise, over the last year XERIS BIOPHARMA HLDGS INC COM USD0.0001 has showed a 68.92% increase.
We've gathered analysts' opinions on XERIS BIOPHARMA HLDGS INC COM USD0.0001 future price: according to them, 0A8E price has a max estimate of 6.60 USD and a min estimate of 3.00 USD. Watch 0A8E chart and read a more detailed XERIS BIOPHARMA HLDGS INC COM USD0.0001 stock forecast: see what analysts think of XERIS BIOPHARMA HLDGS INC COM USD0.0001 and suggest that you do with its stocks.
0A8E reached its all-time high on Jun 25, 2021 with the price of 4.760 USD, and its all-time low was 0.970 USD and was reached on Jan 5, 2023. View more price dynamics on 0A8E chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
0A8E stock is 3.57% volatile and has beta coefficient of 1.98. Track XERIS BIOPHARMA HLDGS INC COM USD0.0001 stock price on the chart and check out the list of the most volatile stocks — is XERIS BIOPHARMA HLDGS INC COM USD0.0001 there?
Today XERIS BIOPHARMA HLDGS INC COM USD0.0001 has the market capitalization of 517.31 M, it has increased by 0.29% over the last week.
Yes, you can track XERIS BIOPHARMA HLDGS INC COM USD0.0001 financials in yearly and quarterly reports right on TradingView.
XERIS BIOPHARMA HLDGS INC COM USD0.0001 is going to release the next earnings report on Mar 5, 2025. Keep track of upcoming events with our Earnings Calendar.
0A8E earnings for the last quarter are −0.11 USD per share, whereas the estimation was −0.09 USD resulting in a −26.92% surprise. The estimated earnings for the next quarter are −0.07 USD per share. See more details about XERIS BIOPHARMA HLDGS INC COM USD0.0001 earnings.
XERIS BIOPHARMA HLDGS INC COM USD0.0001 revenue for the last quarter amounts to 52.86 M USD, despite the estimated figure of 51.45 M USD. In the next quarter, revenue is expected to reach 56.74 M USD.
0A8E net income for the last quarter is −15.74 M USD, while the quarter before that showed −15.01 M USD of net income which accounts for −4.89% change. Track more XERIS BIOPHARMA HLDGS INC COM USD0.0001 financial stats to get the full picture.
No, 0A8E doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 26, 2024, the company has 377.00 employees. See our rating of the largest employees — is XERIS BIOPHARMA HLDGS INC COM USD0.0001 on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. XERIS BIOPHARMA HLDGS INC COM USD0.0001 EBITDA is −32.41 M USD, and current EBITDA margin is −18.82%. See more stats in XERIS BIOPHARMA HLDGS INC COM USD0.0001 financial statements.
Like other stocks, 0A8E shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade XERIS BIOPHARMA HLDGS INC COM USD0.0001 stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So XERIS BIOPHARMA HLDGS INC COM USD0.0001 technincal analysis shows the strong buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating XERIS BIOPHARMA HLDGS INC COM USD0.0001 stock shows the buy signal. See more of XERIS BIOPHARMA HLDGS INC COM USD0.0001 technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.